Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of treatments for human disease. The company's four drug programs are: XERMELO? (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy; sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes; LX2761, an orally-delivered small molecule drug candidate, as a treatment for diabetes; as well as LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.
  • TickerLXRX
  • ISINUS5288723027
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Thanks to a better fundamental star rating, LEXICON PHARMS.INCO. sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to LEXICON PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date July 2, 2019, the closing price was USD 6.24 and its expected value was estimated at USD 5.92.

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

Thanks to a better fundamental star rating, LEXICON PHARMS.INCO. sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to LEXICON PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 4 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date July 2, 2019, the closing price was USD 6.24 and its expected value was estimated at USD 5.92.

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch